Immunotherapy
1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Pregene BiopharmaChina - Shenzhen
1 program1
Chimeric Antigen Receptor NK Cell Injection Targeting BCMAPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
Heidelberg PharmaFecal microbiota transfer
Pregene BiopharmaChimeric Antigen Receptor NK Cell Injection Targeting BCMA
Clinical Trials (2)
Total enrollment: 67 patients across 2 trials
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
Start: Jul 2025Est. completion: Mar 202848 patients
Phase 2Recruiting
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
Start: Nov 2022Est. completion: Nov 202319 patients
Phase 1Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 67 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.